Author: nick
[ad_1] The potentate of plunder steals from his people…and America [ad_2] Source link
[ad_1] Rep. Ocasio-Cortez's Purity Trap [ad_2] Source link
[ad_1] The collapse of the Islamabad negotiations between Iran and United States signified an unbridgeable rift, not only between the negotiating parties, but also between two worldviews on resolving conflicts. The last two rounds of negotiations in May and June 2025 and February 2026 had already demonstrated the Trump administration’s propensity to use stick, instead of pen; verbal abuse, instead of respect, and war, instead of diplomacy, a course of conduct that has been aptly called ‘the Trump Doctrine,” which itself manifests the continuation of many of the U.S. policies adopted by previous administrations around unilateralism. Although indirect negotiations and…
[ad_1] Republican Representative María Elvira Salazar said that the Cuban people are waiting for the order from President Donald Trump to overthrow the government in Havana. “Republicans know you are the only person who will be able to free Cuba after 67 years of oppression, and we Republicans in South Florida are supporting you and waiting for you to take the necessary action,” the Florida Congresswoman wrote on X Tuesday. “Cubans on the island are waiting. Cubans in Miami are waiting. We are waiting for you to give the order. And it will be done.” NEW: President Trump announces plans…
[ad_1] Tuesday, May 12th on RealClearPolitics – Joined by RCP Senior Elections Analyst Sean Trende and Rachel Campos-Duffy, author of All American Patriotism:00:00 … [ad_2] Source link
[ad_1] Can a fractious Europe unite to win the war against Russia while rooting out corrupt oligarchy and promoting democracy in Ukraine? [ad_2] Source link
[ad_1] After a counterprotester was killed at the 2017 Unite the Right rally in Charlottesville, many members of the American Civil Liberties Union (ACLU) condemned its Virginia chapter for defending the First Amendment rights of the white supremacists who organized the demonstration. The critics included Waldo Jaquith, who expressed his displeasure by resigning from the ACLU of Virginia’s board of directors. In an interview with Slate’s Dahlia Lithwick a few weeks later, Jaquith noted that “the ACLU gets to pick” which cases it takes. For example, he said, “you will not see the ACLU taking on any Second Amendment cases,…
[ad_1] The Kremlin said some progress has been made toward ending the war in Ukraine and that Russia would welcome President Donald Trump’s assistance in mediating talks. During Russia’s Victory Day celebrations on Saturday, Russian President Vladimir Putin indicated progress had been made towards a negotiated settlement to end the war in Ukraine. On Tuesday, Kremlin Spokesman Dmitry Peskov said Moscow was optimistic the conflict could end soon. Ukrainian President Zelensky expressed doubt that Russia was prepared to end the conflict. “Russia has no intention of ending this war. And we are, unfortunately, preparing for new attacks,” he said Monday. …
[ad_1] Happy Tuesday, and welcome to another edition of Rent Free. This week, we have stories on: A new report finds that Portland, Maine’s inclusionary zoning law is crushing housing development. A New York Times-hosted gubernatorial forum where everyone tried to sound like a YIMBY. President Donald Trump’s rapid reversion to supporting an effective ban on build-to-rent housing. But first, we cover how Massachusetts’ particular approach to zoning reform makes it too easy for local governments to be pricks. Marblehead, Massachusetts, resident David Modica has gone viral for asking at a recent Town Meeting whether people in town were “being…
[ad_1] The recent Food and Drug Administration (FDA) rejection of RP1, an experimental immunotherapy for advanced melanoma, has sparked frustration among oncologists and patients who see it as another promising therapy kept out of reach. Last month, the agency issued a “complete response letter” declining to approve the therapy, citing insufficient evidence of effectiveness and concerns about the trial’s design. Oncologists and researchers have pushed back, arguing that the FDA dismissed encouraging response data and applied standards that may not fit patients with few remaining options. For patients with advanced melanoma who have exhausted standard treatments, that decision is not an abstract regulatory judgment—it can mean…